Association of human, rat, and rabbit apolipoprotein E with β-amyloid

Journal of Neuroscience Research

Volumn 49, Issue 1, 1997, Pages 9-18

  LaDu, Mary Jo ^a   Lukens, John R ^a   Reardon, Catherine A ^a   Getz, Godfrey S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

amyloid; Alzheimer's disease; Apolipoprotein E

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ARTICLE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN LIPID INTERACTION; RABBIT; RAT; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; CELL LINE; CYSTEINE; DISEASE SUSCEPTIBILITY; GENOTYPE; HUMANS; LIPOPROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; RABBITS; RATS; SPECIES SPECIFICITY; TRANSFECTION;

EID: 0030748833     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H     Document Type: Article

References (45)

1. Basu SK, Ho YK, Brown MS, Bilheimer DW, Anderson RGW, Goldstein JL (1982): The biochemical and genetic studies of apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem 257:9788-9795.
2. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM (1985): Apolipoprotien E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76:1501-1513.
3. Corder EH, Saunder SM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1994): Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Gen 7:180-184.
4. Corder EH, Saunder SM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993): Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
5. Dong LM, Weisgraber KH (1996): Human apolipoprotein E4 domain interaction: Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. J Biol Chem 271:19053-19057.
6. Dong LM, Wilson C, Wardell MR, Summons T, Mahley RW, Weisgraber KH, Agard DA (1994): Human apolipoprotein E: Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 269:22358-22365.
7. Evans KC, Berger EP, Cho C, Weisgraber KH, Lansbury PT (1995): Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 92:763-767.
8. Gearing M, Mori H, Mirra SS (1996): Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Annals Neurol 39:395-399.
9. Good TA, Murphy RM (1995): Aggregation state-dependent binding of β-amyloid peptide to protein and lipid components of rat cortical lipid homogenates. Biochern Biophys Res Comm 207:209-215.
10. Hixson JE, Vernier DT (1990): Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545-548.
11. Innerarity TL, Mahley RW (1978): Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 17:1440-1447.
12. Innerarity TL, Pitas RE, Mahley RW (1986): Lipoprotein-receptor interactions. Methods Enzymol 129:542-565.
13. Koudinov A, Matsubara E, Frangione B, Ghiso J (1994): The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein and very high density lipoprotein in normal human plasma. Biochem Biophys Res Comm 205:1164-1171.
14. Koudinov AR, Koudinov NV, Kumar A, Beavis R, Ghiso J (1996): Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: Association with high density lipoproteins. Biochem Biophys Res Comm 223:592-597.
15. Kowal RC, Herz J, Weisgraber KH, Mahley RW, Brown MS, Goldstein JL (1990): Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem 265:10771-10779.
16. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE (1994): Isoform-specific binding of apolipoprotein E to β-amyloid. J Biol Chem 269:23403-23406.
17. LaDu MJ, Lukens JR, Pederson TM, Reardon CA, Getz GS, Falduto MT (1995): Particle size distribution of native apolipoprotein E in the presence of β-amyloid peptide. Soc Neurosci Abst 21(1):5.
18. LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS, Falduto MT (1995): Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J Biol Chem 270:9039-9042.
19. Laemmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
20. Ma J, Yee A, Brewer HB, Jr., Das S, Potter H (1994): Amyloid-associated proteins al-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94.
21. Ma JH, Brewer B, Jr., Potter H (1996): Alzheimer Ab neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Aβ-related peptides. Neurobiol Aging 17:773-780.
22. Miyata M, Smith JD (1996): Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Gen 14:55-61.
23. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991): Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166.
24. Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, Gandy SE, Lannfelt L, Terenius L, Nordstedt C (1995): Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron 15:219-228.
25. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987): Lipoproteins and their receptors in the central nervous system-Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 262:14352-14360.
26. Poirier J, Hess M, May P, Finch CE (1991): Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Mol Brain Res 11:97-106.
27. Puttfarcken PS, Manelli AM, Pederson AS, Falduto MT, Getz GS, LaDu MJ (1997): Effect of apolipoprotein E on neurite outgrowth and β-amyloid induced toxicity in developing rat primary hippocampal cultures. J Neurochem 68:760-769.
28. Rall SC, Jr., Weisgraber KH, Mahley RW (1986): Isolation and characterization of apolipoprotein E. Methods Enzymol 128:273-287.
29. Reardon CA, Lau Y-F, Paik Y-K, Weisgraber KH, Mahley RW, Taylor JM (1986): Expression of human apolipoprotein E gene in cultured mammalian cells, J Biol Chem 261:9858-9864.
30. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993): Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11:575-580.
31. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ (1994): Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94:860-869.
32. Saunders AM, Strittmatter WJ, Schmechel D, St, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD (1993): Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43:1467-1472.
33. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993): Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653.
34. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993): Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
35. Terzi E, Holzemann G, Seelig J (1995): Self-association of β-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252:633-642.
36. Utermann G (1985): Apolipoprotein E mutants, hyperlipidemia and arteriosclerosis. Adv Exp Med Biol 83:173-188.
37. Weisgraber KH (1994): Apolipoprotein E: Structure-function relationships. Adv Protein Chem 45:249-302.
38. Weisgraber KH, Mahley RW (1986): Characterization of apolipoprotein E-containing lipoproteins. Methods Enzymol 129:145-166.
39. Whiston JS, Mims MP, Strittmatter WJ, Yamaki T, Morrisett JD, Appel SH (1994): Attenuation of the neurotoxic effect of Aβ amyloid peptide by apolipoprotein E. Biochem Biophys Res Comm 177:163-170.
40. Wisniewski T, Castaño EM, Golabek A, Vogel T, Frangione B (1994): Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Path 145:1030-1035.
41. Wisniewski T, Frangione B (1992): Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloidosis. Neurosci Lett 135:235-238.
42. Wisniewski T, Golabeck A, Matsubara E, Ghiso J, Frangione B (1993): Apolipoprotein E: Binding to soluble Alzheimer's β-amyloid. Biochem Biophys Res Comm 192:359-365.
43. Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B (1995): Is Alzheimer's disease an apolipoprotein E amyloidosis? Lancet 345:956-958.
44. Yanagisawa K, Odaka A, Suzuki N, Ihara Y (1995): GM1 gangliosidebound amyloid β-protein (Aβ): A possible form of preamyloid in Alzheimer's disease. Nature Med 1:1062-1066.
45. Zhou Z, Smith JD, Greengard P, Candy S (1996): Alzheimer amyloid-β peptide forms denaturant-resistant complex with type E3 but not type E4 isoform of native apolipoprotein E. Mol Med 2:175-180.